EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion

Qi Pan iD, Ye Zhu, Ziqin Zhou iD, Yao Jiang iD, Yuejin Yang iD, Ling Yu, Yuanwei Pan, Guihao Chen iD

Advanced Science · 2026-11-16

DOI: 10.1002/advs.78697 ↗

At a glance

Journal article in Advanced Science, published online on 2026-11-16. Written by Qi Pan and 7 co-authors. Institution: Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academ…. 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: CAMS Innovation Fund for Medical Sciences (CIFMS), State Key Laboratory of Cardiovascular Disease, Fundamental Research Funds for the Central Universities, Peking Union Medical College.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Acute myocardial infarction (AMI) causes heart failure and mortality, driven by ischemia/reperfusion (I/R) injury and CD47/Signal regulator protein α (SIRPα)‐impaired efferocytosis that together sustain tissue damage. Endogenous plasma small extracellular vesicles (P‐EVs) offer an endogenous, multifunctional option, yet their cardioprotective efficacy is limited by low cardiac accumulation. Herein, a nanosystem (SαV‐DAb) was developed by functionalizing SIRPα‐variant‐overexpressing nanovesicles (SαV) with dual antibodies (DAb) against CD42b (platelet marker) and CD63 (EV marker) via a reactive oxygen species (ROS)‐cleavable linkage. This configuration allows the nanovesicles to hitchhike on circulating platelets for targeted delivery to the ischemic heart, while simultaneously capturing and enriching protective circulating P‐EVs in the lesion. SαV could bind to CD47, avoiding the SIRPα activation on macrophages and promoting efferocytosis. SαV‐DAb demonstrated significantly enhanced cardiac accumulation and promoted targeted delivery of P‐EVs to the ischemic myocardium. Treatment with SαV‐DAb elicited a coordinated therapeutic response, including anti‐apoptosis, pro‐angiogenesis, and pro‐efferocytosis, ultimately leading to attenuated ventricular fibrosis and improved systolic function after I/R injury, with no observable toxicity. This strategy simplifies the preparation workflow by avoiding prior isolation of PLTs and protective vesicles, and provides a conceptual framework for endogenous‐system‐based nanomedicine in cardiac repair.

Subjects

Author keywords

cardiac ischemia/reperfusion injurycardioprotectionefferocytosisextracellular vesiclesplatelet

Authors and institutions

  • Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Peopl…
  • Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, People's Republic of China.
  • Department of Biomedical Engineering, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, People's Republic of China.
  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong, People's Republic of China.
  • State Key Laboratory of Dampness Syndrome of Chinese Medicine, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangdong, People's Republic of China.
  • School of Basic Medical Sciences, Institute of Biomedical Innovation, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.

ORCID profiles: Qi Pan, Ziqin Zhou, Yao Jiang, Yuejin Yang, Guihao Chen

Funding

  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • State Key Laboratory of Cardiovascular Disease
  • Fundamental Research Funds for the Central Universities, Peking Union Medical College
  • National Natural Science Foundation of China
  • Young Talents Cultivation Project for Outstanding Individuals in Guangzhou University of Chinese Medicine
  • Major Science and Technology Projects of Chinese Medicine in Guangzhou Region

Cite

APA

Pan, Q., Zhu, Y., Zhou, Z., Jiang, Y., Yang, Y., Yu, L., Pan, Y., & Chen, G. (2026). Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion. Advanced Science. https://doi.org/10.1002/advs.78697

Vancouver

Pan Q, Zhu Y, Zhou Z, Jiang Y, Yang Y, Yu L, et al. Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion. Advanced Science. 2026. doi:10.1002/advs.78697

BibTeX
@article{Pan2026,
  author = {Pan, Qi and Zhu, Ye and Zhou, Ziqin and Jiang, Yao and Yang, Yuejin and Yu, Ling and Pan, Yuanwei and Chen, Guihao},
  title = {Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.78697}
}
Start for free →